Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Hold" by Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have earned a consensus rating of "Hold" from the nine analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $9.29.

NMRA has been the subject of several recent analyst reports. Needham & Company LLC restated a "buy" rating and issued a $5.00 target price on shares of Neumora Therapeutics in a research note on Tuesday, May 13th. HC Wainwright lowered their target price on shares of Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Stifel Nicolaus downgraded shares of Neumora Therapeutics from a "buy" rating to a "hold" rating and lowered their target price for the company from $6.00 to $2.00 in a research note on Friday, March 7th. Royal Bank Of Canada restated a "sector perform" rating and issued a $4.00 target price on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. Finally, Bank of America reiterated an "underperform" rating and set a $1.00 price objective (down from $7.00) on shares of Neumora Therapeutics in a research note on Wednesday, April 2nd.

Neumora Therapeutics Stock Down 0.1%

Shares of NMRA stock opened at $0.81 on Thursday. The firm has a market cap of $130.68 million, a price-to-earnings ratio of -0.50 and a beta of 2.73. Neumora Therapeutics has a 52-week low of $0.61 and a 52-week high of $17.19. The company's 50 day moving average is $0.75 and its 200 day moving average is $2.41.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.02). Analysts anticipate that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Neumora Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in NMRA. Capital International Investors lifted its position in Neumora Therapeutics by 692.1% during the fourth quarter. Capital International Investors now owns 3,700,359 shares of the company's stock valued at $39,224,000 after purchasing an additional 3,233,179 shares during the period. Lunate Capital Ltd acquired a new position in Neumora Therapeutics during the first quarter valued at $2,124,000. Graham Capital Management L.P. lifted its position in Neumora Therapeutics by 1,643.7% during the first quarter. Graham Capital Management L.P. now owns 1,162,499 shares of the company's stock valued at $1,162,000 after purchasing an additional 1,095,830 shares during the period. AQR Capital Management LLC acquired a new position in Neumora Therapeutics during the first quarter valued at $463,000. Finally, Stempoint Capital LP acquired a new position in Neumora Therapeutics during the fourth quarter valued at $4,538,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.